Effects of flecainide on defibrillation thresholds in the anesthetized dog

Division of Cardiology, University of Colorado Health Sciences Center, Denver 80262.

The effects of flecainide on defibrillation thresholds in 21 open chest, anesthetized dogs were studied. Defibrillation was accomplished using nontruncated exponential pulses delivered through two epicardial patches. Multiple shocks of varying energy were administered after 10 s of ventricular fibrillation in random order. The percent success was plotted against the energy delivered for each dog. A sigmoidal curve was fit to the data and the energy associated with 50% success (E50) calculated. Flecainide (n = 16) or saline solution (n = 5) was then infused and E50 again determined. Flecainide infusion produced mean (+/- standard error of the mean) plasma levels of 610 +/- 111 ng/ml. Defibrillation thresholds were obtainable in 10 of 16 dogs that received flecainide infusion. Flecainide infusion increased E50 by 75% (from 6.5 +/- 1.9 to 11.4 +/- 2.6 J) (P less than 0.05). Infusion of saline solution did not significantly affect defibrillation energy. Of 16 dogs that received flecainide infusion, 12 had one or more complications: 6 had ventricular fibrillation resistant to defibrillation, 6 developed severe hypotension after successful defibrillation and 5 had spontaneous ventricular fibrillation after successful defibrillation. These effects were not seen in any control dogs. Flecainide infusion significantly increases defibrillation threshold and has important adverse arrhythmic and hemodynamic effects in this experimental preparation.

This article has been cited by other articles:

				J. J. Sanchez-Munoz, J. L. Rojo-Alvarez, A. Garcia-Alberola, E. Everss, F. Alonso-Atienza, M. Ortiz, J. Martinez-Sanchez, J. Ramos-Lopez, and M. Valdes-Chavarri Spectral analysis of intracardiac electrograms during induced and spontaneous ventricular fibrillation in humans Europace, March 1, 2009; 11(3): 328 - 331. [Abstract] [Full Text] [PDF]

				L.-P. Lai, J.-L. Lin, W.-P. Lien, Y.-Z. Tseng, and S. K. S. Huang Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1434 - 1441. [Abstract] [Full Text] [PDF]

				G. Boriani, M. Biffi, A. Capucci, G. Bronzetti, G. M. Ayers, R. Zannoli, A. Branzi, and B. Magnani Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation J. Am. Coll. Cardiol., February 1, 1999; 33(2): 333 - 341. [Abstract] [Full Text] [PDF]

				D A Chamberlain Antiarrhythmic drugs in resuscitation Heart, October 1, 1998; 80(4): 408 - 411. [Full Text]

				M. R. Ujhelyi, M. Schur, T. Frede, M. Gabel, and M. L. Markel Differential Effects of Lidocaine on Defibrillation Threshold With Monophasic Versus Biphasic Shock Waveforms Circulation, September 15, 1995; 92(6): 1644 - 1650. [Abstract] [Full Text]